Want to see DE:FRE full AI Analyst Report?
FRE Stock Chart & Stats
€43.80
€0.45(1.03%)
At close: 4:00 PM EDT
€43.80
€0.45(1.03%)
Day’s Range― - ―
52-Week Range€35.11 - €52.96
Previous CloseN/A
Volume752.33K
Average Volume (3M)750.62K
Market Cap
€24.82B
Enterprise Value€35.49K
Total Cash (Recent Filing)€2.06B
Total Debt (Recent Filing)€11.90B
Price to Earnings (P/E)16.7
Beta0.83
Next Earnings
Aug 05, 2026EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend Yield2.36%
Share Statistics
EPS (TTM)2.66
Shares Outstanding563,237,300
10 Day Avg. Volume787,875
30 Day Avg. Volume750,621
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.44
Price to Sales (P/S)1.21
P/FCF Ratio23.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€54.94Price Target Upside25.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)3.54
Revenue Forecast (FY)€23.69B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow StrengthTTM free cash flow of €1.45B and consistently positive operating cash flow create durable internal funding for capex, R&D, and dividends. Strong cash conversion supports deleveraging and shields investments from short-term market volatility, improving long-term resilience.
Improved Leverage And Recovering ROEMarked reduction in leverage versus 2021–22 and recovery in ROE indicate healthier capital structure and better returns generation. Lower leverage reduces refinancing and interest risk, expanding strategic flexibility for investments, acquisitions, or further shareholder distributions over the medium term.
U.S. Biosimilars Commercialization ExpansionExclusive U.S. commercialization of an FDA‑approved rituximab biosimilar is a structural revenue opportunity that broadens Fresenius Kabi's oncology/immunology portfolio. It leverages recurring biologics demand and distribution scale, supporting sustainable revenue diversification in the large U.S. biologics market.
Bears Say
High Absolute Debt LoadDespite improved ratios, an absolute debt burden near €11.9B constrains financial flexibility. High nominal debt raises interest and refinancing exposure and limits capacity for large M&A or cyclical investments, making the company more sensitive to macro shocks or rising rates.
Choppy Multi-Year Revenue TrajectoryAn inconsistent top-line, including a sharp 2023 decline, undermines predictability for margins and capital allocation. Fluctuating revenue complicates multi-year planning, reduces visibility into sustainable growth drivers, and increases reliance on cyclical recovery rather than steady expansion.
Moderate Profitability MarginsMargins and returns have recovered but remain moderate. Limited profitability cushions reduce the company's ability to absorb reimbursement cuts, cost inflation, or competitive pricing pressure, constraining internal funding for growth and making operating improvements necessary to boost long-term returns.
Fresenius SE & Co. KGaA News
FRE FAQ
What was Fresenius SE & Co. KGaA’s price range in the past 12 months?
Fresenius SE & Co. KGaA lowest stock price was €35.11 and its highest was €52.96 in the past 12 months.
What is Fresenius SE & Co. KGaA’s market cap?
Fresenius SE & Co. KGaA’s market cap is €24.82B.
When is Fresenius SE & Co. KGaA’s upcoming earnings report date?
Fresenius SE & Co. KGaA’s upcoming earnings report date is Aug 05, 2026 which is today.
How were Fresenius SE & Co. KGaA’s earnings last quarter?
Currently, no data Available
Is Fresenius SE & Co. KGaA overvalued?
According to Wall Street analysts Fresenius SE & Co. KGaA’s price is currently Undervalued.
Does Fresenius SE & Co. KGaA pay dividends?
Fresenius SE & Co. KGaA pays a Annually dividend of €1.05 which represents an annual dividend yield of 2.36%. See more information on Fresenius SE & Co. KGaA dividends here
What is Fresenius SE & Co. KGaA’s EPS estimate?
Fresenius SE & Co. KGaA’s EPS estimate is 0.88.
How many shares outstanding does Fresenius SE & Co. KGaA have?
Fresenius SE & Co. KGaA has 563,237,300 shares outstanding.
What happened to Fresenius SE & Co. KGaA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Fresenius SE & Co. KGaA?
Currently, no hedge funds are holding shares in DE:FRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius SE & Co. KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€54.94 (25.44% Upside)
€54.94 (25.44% Upside)
Insider Transactions
Bought Shares
Worth €499.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.67%
12-Months-Change
Fundamentals
Return on Equity
2.36%
Trailing 12-Months
Asset Growth
-1.94%
Trailing 12-Months
Company Description
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
FRE Stock 12 Month Forecast
Average Price Target
€54.94
▲(25.44% Upside)
Technical Analysis
CompuGroup Medical
―
Draegerwerk AG & Co. KGaA
―
Fresenius Medical Care AG & Co. KGaA
―
MEDICLIN
―
RHON-KLINIKUM AG
―








